| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre … R Rosell, E Carcereny, R Gervais, A Vergnenegre, B Massuti, E Felip, ... The lancet oncology 13 (3), 239-246, 2012 | 6299 | 2012 |
| Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials RC Doebele, A Drilon, L Paz-Ares, S Siena, AT Shaw, AF Farago, ... The Lancet Oncology 21 (2), 271-282, 2020 | 1404 | 2020 |
| Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non–small cell lung cancer L Mezquita, E Auclin, R Ferrara, M Charrier, J Remon, D Planchard, ... JAMA oncology 4 (3), 351-357, 2018 | 714 | 2018 |
| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ... The Lancet Oncology 21 (7), 914-922, 2020 | 653 | 2020 |
| Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study K Park, EB Haura, NB Leighl, P Mitchell, CA Shu, N Girard, S Viteri, ... Journal of Clinical Oncology 39 (30), 3391, 2021 | 458 | 2021 |
| Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study L Crinò, E Dansin, P Garrido, F Griesinger, J Laskin, N Pavlakis, ... The lancet oncology 11 (8), 733-740, 2010 | 380 | 2010 |
| Patient involvement in clinical research: why, when, and how JA Sacristán, A Aguarón, C Avendaño-Solá, P Garrido, J Carrión, ... Patient preference and adherence, 631-640, 2016 | 349 | 2016 |
| Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced non–small cell lung cancer: the SELECT-1 randomized … PA Jänne, MM van den Heuvel, F Barlesi, M Cobo, J Mazieres, L Crinò, ... Jama 317 (18), 1844-1853, 2017 | 341 | 2017 |
| Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus G Curigliano, S Banerjee, A Cervantes, MC Garassino, P Garrido, ... Annals of Oncology 31 (10), 1320-1335, 2020 | 312 | 2020 |
| The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC C Manegold, AMC Dingemans, JE Gray, K Nakagawa, M Nicolson, ... Journal of Thoracic Oncology 12 (2), 194-207, 2017 | 235 | 2017 |
| Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the … R Rosell, R Gervais, A Vergnenegre, B Massuti, E Felip, F Cardenal, ... Journal of clinical oncology 29 (15_suppl), 7503-7503, 2011 | 210 | 2011 |
| Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non–small cell lung cancer: efficacy, safety, and biomarkers S Peters, R Stahel, L Bubendorf, P Bonomi, A Villegas, DM Kowalski, ... Clinical Cancer Research 25 (1), 64-72, 2019 | 189 | 2019 |
| Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis M Duruisseaux, A Martínez-Cardús, ME Calleja-Cervantes, S Moran, ... The Lancet Respiratory Medicine 6 (10), 771-781, 2018 | 188 | 2018 |
| Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, ... Annals of Oncology 27 (3), 417-423, 2016 | 162 | 2016 |
| Usefulness of megestrol acetate in cancer cachexia and anorexia: a placebo-controlled study J Feliu, M Gonzalez-Baron, A Berrocal, A Artal, A Ordonez, P Garrido, ... American journal of clinical oncology 15 (5), 436-440, 1992 | 139 | 1992 |
| Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non–small-cell lung cancer patients: The Spanish Lung … P Garrido, JL González-Larriba, A Insa, M Provencio, A Torres, D Isla, ... Journal of clinical oncology 25 (30), 4736-4742, 2007 | 130 | 2007 |
| Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial V Subbiah, PA Cassier, S Siena, E Garralda, L Paz-Ares, P Garrido, ... Nature medicine 28 (8), 1640-1645, 2022 | 129 | 2022 |
| Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: An alternative therapy M Nogué‐Aliguer, J Carles, A Arrivi, O Juan, L Alonso, A Font, B Mellado, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 113 | 2003 |
| Treatment characteristics and real-world progression-free survival in patients with unresectable stage III NSCLC who received durvalumab after chemoradiotherapy: findings from … N Girard, J Bar, P Garrido, MC Garassino, F McDonald, F Mornex, ... Journal of Thoracic Oncology 18 (2), 181-193, 2023 | 103 | 2023 |
| Efficacy of oral tegafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study M Gonzalez-Baron, J Feliu, I De la Gandara, E Espinosa, A Colmenarejo, ... European Journal of Cancer 31 (13-14), 2215-2219, 1995 | 103 | 1995 |
